Last reviewed · How we verify
PRG-1801
At a glance
| Generic name | PRG-1801 |
|---|---|
| Also known as | BCMA-targeting CAR-T Cells |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP) (EARLY_PHASE1)
- Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease (EARLY_PHASE1)
- Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |